BioTuesdays

Tag - ATBPF

Antibe to have Phase 2 pain data by third quarter

By Len Zehr Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee...